Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People | Bloomberg Businessweek

Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF (http://bit.ly/3vTiACF).
Bloomberg News Health Care Reporter Madison Muller discusses that patients taking Eli Lilly’s blockbuster weight-loss shot were 94% less likely to develop diabetes in a three-year study that illuminates the long-term health benefits of treating obesity.
Hosts: Tim Stenovec and Katie Greifeld. Producer: Paul Brennan.

See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information.
Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more by harnessing the power of Bloomberg Businessweek reporters and editors.

Subscribe to Bloomberg Podcasts: https://bit.ly/BloombergPodcasts
Listen to more of Bloomberg Businessweek: https://youtube.com/playlist?list=PLe4PRejZgr0NDtGW4nghKtCxl6SCdFJfq

#Bloomberg #Podcast #News #Businessweek

Visit us: https://www.bloomberg.com/podcasts

Follow Bloomberg Podcasts on Twitter: https://twitter.com/podcasts

Visit our other YouTube channels:
Bloomberg Television: https://www.youtube.com/@markets
Bloomberg Originals: https://www.youtube.com/bloomberg
Quicktake: https://www.youtube.com/@BloombergQuicktake

For coverage on news, markets and more: http://www.bloomberg.com/video

Видео Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People | Bloomberg Businessweek канала Bloomberg Podcasts